LLY vs. JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, JAZZ, CORT, and PRGO
Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
Eli Lilly and Company vs.
Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
In the previous week, Eli Lilly and Company had 41 more articles in the media than Johnson & Johnson. MarketBeat recorded 59 mentions for Eli Lilly and Company and 18 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.93 beat Eli Lilly and Company's score of 0.62 indicating that Johnson & Johnson is being referred to more favorably in the media.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.8%. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Eli Lilly and Company pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 63 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Johnson & Johnson currently has a consensus target price of $174.73, suggesting a potential upside of 20.95%. Eli Lilly and Company has a consensus target price of $1,002.22, suggesting a potential upside of 30.54%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Johnson & Johnson.
Eli Lilly and Company has a net margin of 20.48% compared to Johnson & Johnson's net margin of 19.14%. Eli Lilly and Company's return on equity of 71.08% beat Johnson & Johnson's return on equity.
Eli Lilly and Company received 97 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.65% of users gave Eli Lilly and Company an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote.
Summary
Eli Lilly and Company beats Johnson & Johnson on 13 of the 21 factors compared between the two stocks.
Get Eli Lilly and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eli Lilly and Company Competitors List
Related Companies and Tools
This page (NYSE:LLY) was last updated on 12/21/2024 by MarketBeat.com Staff
Free LLY Stock Alerts